(NLST) entry criteria. 1 – 4 All 3 organizations have expanded their screening recommendations to include older patients, younger patients, and/or patients with additional risk factors for lung cancer. Inclusion of these additional populations has
Search Results
NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening
Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee
Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud, and Brant A. Inman
recurrence rates. In addition, the authors seek to analyze whether this effect varies by drug or by baseline patient risk factors. Methods Literature Search Strategy The authors searched the Cochrane Controlled Trials Register (CENTRAL
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde
Rasha Abo El Hassan, Noura Anwar Abdel-Fatah, Hadeer Khalefa Ahmed, May Shawki, and Lamia El Wkeel
risk factors for Paclitaxel induced peripheral neuropathy (PIPN). Methods : NCT03492047 is prospective randomized controlled open label study was conducted on 75 breast cancer patients receiving adjuvant paclitaxel 80 mg/m2 weekly for 12 weeks
A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status
Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey
-intent resection of CLM, it is critical to explore this issue further and develop a potential surveillance algorithm specific to this patient cohort. Within this context, the primary aim of this study was to assess the changes in recurrence risks and risk factors
Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia
Ruben Niesvizky and Ashraf Z. Badros
preventing, identifying, and managing them. Venous Thromboembolism VTE typically manifests as deep vein thrombosis (DVT) or pulmonary embolism (PE). Both cancer and cancer treatments have been identified as discrete risk factors. 1 Current evidence
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy
Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian
chi-square test for categorical or 2-sided Student t tests for continuous variables. Univariable Cox proportional hazards regression was used to characterize the association between patient, disease, and CAR T-cell–related risk factors and 1-year PFS
Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im, and Jung-Hwan Yoon
, 30 Patients with cirrhosis are more likely to develop hepatic decompensation, resulting in hepatic failure. 5 Risk Factors for HBV Reactivation: Patient Factors, Cancer Type, and Treatment Factors Identifying risk factors for HBV reactivation
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis
Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang
study period (median follow-up, 15 months [IQR, 4 months to 4.2 years]); all were attributed to the patients’ malignancies. Patient Characteristics According to Esophagitis Risk Factors We compared the clinical characteristics of patients with risk
Long-Term Outcomes of Myeloid Growth Factor Treatment
Gary H. Lyman and David C. Dale
of AML/MDS increased significantly with the cumulative dose of epirubicin. In multivariate regression analysis, the cumulative doses of epirubicin and cyclophosphamide, but not of G-CSF, were independent risk factors for AML/MDS. Because G-CSF enables
NCCN Task Force Report: Breast Cancer in the Older Woman
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
point system for 4-year mortality risk: 0 to 5 points: 4% or less; 6 to 9 points is 15%; 10 to 13 points is 42%; and 14 or more points is 64%. Table 4. Independent Risk Factors for 4-Year Mortality The Adjuvant! Online program provides estimates of the
